迈威生物于2025年5月10日披露了《关于公司董事长兼总经理收到立案告知书的公告》（公告编号： 2025-023），公司董事长兼总经理刘大涛因涉嫌短线交易，中国证券监督管理委员会（以下简称"中国 证监会"）决定对其立案。 近日，公司董事长兼总经理刘大涛收到中国证监会上海监管局出具的《行政处罚决定书》（编号：沪 [2025]16号）。 经查明，刘大涛存在以下违法事实：2022年1月18日迈威（上海）生物科技股份有限公司（以下简称"迈 威生物"或"公司"）上市至2022年7月18日期间，你作为公司董事、总经理，使用周某证券账户（沪市股 东代码为A748696615）累计买入"迈威生物"976,567股，合计成交19,297,719.97元，累计卖出"迈威生 物"634,265股，合计成交13,883,564.69元。 刘大涛上述行为属于《证券法》第四十四条第一款、第二款规定的董事、高级管理人员将其持有的或者 利用他人账户持有的该公司的股票在买入后六个月内卖出的行为，构成《证券法》第一百八十九条所述 的违法行为。根据当事人违法行为的事实、性质、情节与社会危害程度，依据《证券法》第一百八十九 条的规定，中国证监会上海 ...

8月4日，沪深两融数据显示，迈威生物获融资买入额0.81亿元，居两市第202位，当日融资偿还额0.68亿 元，净买入1283.86万元。 最近三个交易日，31日-4日，迈威生物分别获融资买入0.80亿元、0.76亿元、0.81亿元。 融券方面，当日融券卖出0.05万股，净卖出0.05万股。 本文源自：金融界 作者：智投君 ...

Group 1: Pharmaceutical Regulations - Starting from August 1, all retail pharmacies in Foshan will implement a real-name registration system for the sale of 47 key controlled drugs, primarily for treating symptoms of Chikungunya fever [1] - The list of controlled drugs includes common medications such as Ibuprofen, Compound Cold Medicine, and Lianhua Qingwen capsules [1] Group 2: Clinical Trials and Drug Approvals - Kangning Jereh's innovative drug JSKN022, a PD-L1/αvβ6 dual-specific antibody drug conjugate, has received acceptance for clinical trial application from the National Medical Products Administration [3] - Yipin Hong's innovative drug APH03621 for endometriosis treatment has also received clinical trial registration acceptance from the National Medical Products Administration [5] - Lianhua Pharmaceutical's subsidiary has passed the consistency evaluation for the generic drug Lincomycin Hydrochloride Injection [4] Group 3: Financial Performance - China Resources Medical expects a profit decline of 20% to 25% for the first half of the year, with a significant drop of 55% to 60% when excluding one-time gains [6] - Zhenghai Bio reported a net profit of 46.49 million yuan for the first half of 2025, a decrease of 45.97% year-on-year, with revenue of 188 million yuan, down 5.14% [8] Group 4: Corporate Actions - Kexing Bio has spent 47.38 million yuan to repurchase 1.27 million shares, representing 0.63% of its total share capital [8] - WuXi AppTec has repurchased 6.51 million A-shares for a total of 497 million yuan [10] - Tian Tan Bio has decided to abandon the acquisition opportunity of Pailin Bio due to potential competition with its core business [9] Group 5: Industry Developments - Significant progress has been made in HIV vaccine research in China, with the completion of the first phase clinical trial for a replicating Tian Tan smallpox vaccine carrier HIV vaccine [11][13] - Sanofi announced the discontinuation of its PCSK9 inhibitor drug Alirocumab in China due to global supply issues and a strategic shift in its cardiovascular product line [12]

Core Viewpoint - The announcement details the administrative penalty imposed on Liu Datao, the Chairman and General Manager of Maiwei (Shanghai) Biotechnology Co., Ltd., for engaging in short-term trading of the company's stock, which violates the Securities Law of the People's Republic of China [1][2]. Summary by Sections Administrative Penalty Details - Liu Datao was found to have bought 976,567 shares of "Maiwei Biotechnology" for a total of 19,297,719.97 yuan and sold 634,265 shares for 13,883,564.69 yuan between January 18, 2022, and July 18, 2022 [2]. - His actions were classified as violations under Article 44 and Article 189 of the Securities Law, leading to a warning and a fine of 600,000 yuan [2]. Compliance and Disclosure - The company emphasizes its commitment to comply with relevant laws and regulations, ensuring timely information disclosure [4]. - The administrative penalty pertains solely to Liu Datao and is not expected to significantly impact the company's daily operations [3].

北京商报讯（记者 丁宁）8月4日晚间，迈威生物（688062）发布公告称，近日，公司董事长兼总经理 刘大涛收到上海证监局出具的《行政处罚决定书》。 经查明，刘大涛存在以下违法事实。2022年1月18日迈威生物上市至2022年7月18日期间，刘大涛作为公 司董事、总经理，使用周某证券账户（沪市股东代码为A748696615）累计买入"迈威生物"97.66万股， 合计成交1929.77万元，累计卖出"迈威生物"63.43万股，合计成交1388.36万元。 上海证监局表示，刘大涛上述行为属于《证券法》第四十四条第一款、第二款规定的董事、高级管理人 员将其持有的或者利用他人账户持有的该公司的股票在买入后六个月内卖出的行为，构成《证券法》第 一百八十九条所述的违法行为。根据当事人违法行为的事实、性质、情节与社会危害程度，依据《证券 法》第一百八十九条的规定，决定对刘大涛给予警告，并处以六十万元罚款。 ...

新京报贝壳财经讯 迈威生物公告，公司董事长兼总经理刘大涛因涉嫌短线交易收到中国证监会上海监 管局出具的《行政处罚决定书》。根据《行政处罚决定书》内容，刘大涛在2022年1月18日至2022年7月 18日期间，使用周某证券账户累计买入"迈威生物"97.66万股，合计成交1929.77万元，累计卖出"迈威生 物"63.43万股，合计成交1388.36万元。依据《证券法》第四十四条和第一百八十九条的规定，刘大涛被 给予警告，并处以六十万元罚款。上述决定不会对公司日常经营活动产生重大影响。 ...

Core Viewpoint - Liu Datao, the chairman and general manager of Maiwei Biotech, received an administrative penalty from the China Securities Regulatory Commission (CSRC) for engaging in short-term trading of the company's stock, which is a violation of the Securities Law [2][3][5] Summary by Sections Administrative Penalty Details - The CSRC found that from January 18, 2022, to July 18, 2022, Liu Datao used a third-party securities account to buy a total of 976,567 shares of Maiwei Biotech, amounting to approximately 19.3 million yuan, and sold 634,265 shares for about 13.88 million yuan [2][3][4] - Liu's actions were classified as illegal under Article 44 and Article 189 of the Securities Law, which prohibits directors and senior management from selling company stock within six months of purchase [5] Penalty Imposed - Liu Datao was issued a warning and fined 600,000 yuan for his violations, with the requirement to pay the fine within 15 days of receiving the penalty notice [5][6] - The penalty is solely directed at Liu Datao and does not significantly impact the company's daily operations [2][6] Company Compliance and Disclosure - The company emphasizes its commitment to comply with relevant laws and regulations and has fulfilled its obligation for timely information disclosure regarding the incident [6][7]

近日，公司董事长兼总经理刘大涛先生收到中国证监会上海监管局出具的 《行政处罚决定书》（编号：沪[2025]16 号）。现将相关内容说明如下： 一、《行政处罚决定书》的主要内容 证券代码：688062 证券简称：迈威生物 公告编号：2025-039 迈威（上海）生物科技股份有限公司 关于公司董事长兼总经理收到 行政处罚决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 10 日披露了《关于公司董事长兼总经理收到立案告知书的公告》（公告编号： 2025-023），公司董事长兼总经理刘大涛先生因涉嫌短线交易，中国证券监督管 理委员会（以下简称"中国证监会"）决定对其立案。 "依据《中华人民共和国证券法》（以下简称《证券法》）的有关规定，本 局对刘大涛短线交易"迈威生物"行为进行了立案调查，并依法向当事人告知 了作出行政处罚的事实、理由、依据及当事人依法享有的权利。当事人未提出 陈述、申辩意见，也未要求听证。本案现已调查、办理终结。 对刘大涛给 ...

Core Viewpoint - The chairman and general manager of Maiwei Bio, Liu Datao, has been penalized by the China Securities Regulatory Commission for suspected short-term trading activities, which involved significant transactions in the company's shares [1] Summary by Relevant Sections Regulatory Action - Liu Datao was issued an administrative penalty decision by the Shanghai Regulatory Bureau of the China Securities Regulatory Commission for short-term trading [1] - The penalty includes a warning and a fine of 600,000 yuan [1] Trading Activities - Between January 18, 2022, and July 18, 2022, Liu Datao used a specific securities account to buy a total of 976,600 shares of Maiwei Bio, amounting to 19.2977 million yuan [1] - During the same period, he sold 634,300 shares, with total sales amounting to 13.8836 million yuan [1] Impact on Company Operations - The regulatory decision is stated to have no significant impact on the company's daily operations [1]

8月1日，沪深两融数据显示，迈威生物获融资买入额0.76亿元，居两市第223位，当日融资偿还额0.97亿 元，净卖出2039.88万元。 最近三个交易日，30日-1日，迈威生物分别获融资买入0.76亿元、0.80亿元、0.76亿元。 融券方面，当日融券卖出0.00万股，净买入0.15万股。 本文源自：金融界 作者：智投君 ...